Extended Data Fig. 2: Characterization of S. enteritidis 3934 ΔXIV (ΔXIV) for A20 lymphoma therapy.
From: Engineered bacteria for near-infrared light-inducible expression of cancer therapeutics
a, Bacterial abundance and metabolic activity of ΔXIV within A20 tumors at the indicated time points. A20 tumor-bearing mice received an intratumoral injection of 5 × 106 c.f.u. of ΔXIV-lux (n = 5 mice per group). Bacterial abundance was measured by colony counting (c.f.u., left axis), and metabolic activity was evaluated by RLU (right axis) at the indicated time points. b, Representative photographs of LB agar plates spread with tissue homogenate of tumors and major organs. For example, 1/10 means that the tissue homogenate supernatant is diluted 10 times with sterile PBS, and then 100 μL supernatant of tissue homogenate with this dilution ratio is plated on the agar. c, Bacterial counts in tumor tissues and five major organs (n = 5 mice per group). Tumors and major organs, including heart, liver, spleen, lung, and kidney, were collected from A20 tumor-bearing mice at the indicated time points after intratumoral injection of 5 × 106 c.f.u. of ΔXIV, homogenization and plating on LB solid medium for colony counting. d, e, IL-6 levels in tumor tissues and serum. A20 tumor-bearing mice received an intratumoral injection of 5 × 106 c.f.u. of ΔXIV (n = 5 mice per group). IL-6 levels in tumor homogenates (d) and serum (e) of mice were quantified at the indicated time points. Data are expressed as means ± s.e.m.; Statistical analyses in d, e were performed using one-way ANOVA followed by Tukey’s test with multiple comparisons.
